ConductScience.org, home

Paper23749673

Immunosuppression and HBV reactivation.

Shouval D and 1 other. Semin Liver Dis, 2013. Cited by 137 papers, by iCite.

Cite this record

ConductScience Library. Immunosuppression and HBV reactivation. Papers, record 23749673. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23749673

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immunosuppression and HBV reactivation.
PubMed
Journal
Semin Liver Dis
PubMed
Year
2013
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
137
iCite
Relative citation ratio, by iCite
4.42
iCite
Revised in PubMed
2022-03-31
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shouval DDaniel
2Shibolet OOren

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hepatitis B virusMajor topic
Hepatitis B, ChronicMajor topic
Immunosuppressive AgentsMajor topic
Virus ActivationMajor topic
Animals
Antiviral Agents
Biomarkers
DNA, Viral
Hepatitis B Surface Antigens
Humans
Recurrence
Risk Factors
Treatment Outcome

Source PubMed

Download CSV of topics

Cited by80

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 137 citations.

PMIDTitleJournalYearIn PapersSource
42444826Efficacy and safety of combining TACE with atezolizumab/bevacizumab versus TACE alone: a retrospective propensity score-matched cohort study in HBV-related hepatocellular carcinoma.Front Oncol2026https://conductscience.org/library/papers/42444826PubMed
42058201Total immunoglobulin G concentration as a correlate of anemia in dialysis patients: machine learning analysis of clinical and serological factors.Front Immunol2026https://conductscience.org/library/papers/42058201PubMed
41443190Functional immune responses induced by a capsid assembly modulator in chronic hepatitis B virus-infected humanized mice.Cell Host Microbe2026https://conductscience.org/library/papers/41443190PubMed
41183666Antineoplastic agents-associated hepatitis B virus reactivation: Research progress and molecular mechanisms.Virus Res2025https://conductscience.org/library/papers/41183666PubMed
41152543The interplay between hepatitis B virus and antitumor drugs in the treatment of hepatocellular carcinoma.Clin Exp Med2025https://conductscience.org/library/papers/41152543PubMed
41039566​​The immune microenvironment of pathogen-associated cancers and current clinical therapeutics.Mol Cancer2025https://conductscience.org/library/papers/41039566PubMed
41003568Prevalence and Screening Rates of Hepatitis B and Hepatitis C Infections in Adult Patients with Solitary Organ Tumors.Trop Med Infect Dis2025https://conductscience.org/library/papers/41003568PubMed
40510114HBV reactivation and its management in HBV-related HCC patients undergoing HAIC-TKI-ICI therapy: A multicenter study.iScience2025https://conductscience.org/library/papers/40510114PubMed
40495049Fatal vanishing bile duct syndrome after cord blood transplantation mimicking HBV reactivation.Clin J Gastroenterol2025https://conductscience.org/library/papers/40495049PubMed
39903324Detection of hepatitis B virus surface antigen, IgM and IgG antibodies to hepatitis B virus core antigen in the clinical classification and epidemiological surveillance of HBV infection.Mol Biol Rep2025https://conductscience.org/library/papers/39903324PubMed
39412690
Hepatitis B surface antigen reverse seroconversion after hematopoietic stem cell transplantation according to the baseline serological marker levels and vaccination status: a single-center database analysis.
Blood Res2024https://conductscience.org/library/papers/39412690PubMed
38482703[Comorbidities in multiple sclerosis and their influence on the choice of treatment].Rev Neurol2024https://conductscience.org/library/papers/38482703PubMed
38376651Preventing viral relapse with prophylactic tenofovir in hepatitis B carriers receiving chemotherapy: a phase IV randomized study in Taiwan.Hepatol Int2024https://conductscience.org/library/papers/38376651PubMed
37731995Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era.World J Gastroenterol2023https://conductscience.org/library/papers/37731995PubMed
37426446The growing burden of generalized myasthenia gravis: a population-based retrospective cohort study in Taiwan.Front Neurol2023https://conductscience.org/library/papers/37426446PubMed
37326752Unusual serological profile in hepatitis B virus (HBV) infection associated with a probable clinical case of acute exacerbation of pre-existing chronic HBV infection.Mol Biol Rep2023https://conductscience.org/library/papers/37326752PubMed
36920988Incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection: A systematic review and meta-analysis.PLoS Med2023https://conductscience.org/library/papers/36920988PubMed
36851587Clinical Utility of Quantitative HBV Core Antibodies for Solving Diagnostic Dilemmas.Viruses2023https://conductscience.org/library/papers/36851587PubMed
36540103Durability of Antibody Response Against Hepatitis B Virus for a Decreased Crowd: A Retrospective Polycentric Cohort Study from a 10-Year Follow-Up Clinical Study.Infect Drug Resist2022https://conductscience.org/library/papers/36540103PubMed
36157140Hepatitis B Reactivation Following Eradication of HCV with Direct-Acting Antiviral Drugs (DAAs) in a Cohort of Patients from Different Institutions in Egypt.J Clin Exp Hepatol2022https://conductscience.org/library/papers/36157140PubMed

See all 80 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23749673

GET https://conductscience.org/api/papers/v1/23749673/cited_by?page=2